Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 4,25 € (+608,33 %). La mediana es de 3,64 € (+506,67 %).
| Comprar |
16 |
| Mantener |
1 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Compass Therapeutics reports positive phase 1 data for CTX-8371, stock remains under pressure
Compass Therapeutics released phase 1 data on CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, showing three responses among 15 evaluable patients, including a >90% reduction in a case of triple-negative breast cancer. In the two highest dose cohorts (3.0 and 10.0 mg/kg) the overall response rate was 33% (2 of 6). No dose-limiting toxicities were observed; adverse events were mostly grade 1–2, with one asymptomatic grade 3 lipase elevation. The company has expanded cohorts for NSCLC, triple-negative breast cancer and Hodgkin lymphoma; additional data are expected in Q4 2026 and the results will be presented on May 30, 2026 at ASCO. Despite the clinical progress, the stock remains under pressure (market cap $326m, YTD loss 65% near a 52-week low) and investors are concerned about rapid cash burn. » Más en de.investing.com
Compass Therapeutics stock falls 80% after mixed COMPANION-002 data and approval concerns
Compass Therapeutics’ shares plunged 80% after the Phase II/III COMPANION-002 study of tovecimig plus paclitaxel in cholangiocarcinoma produced mixed results. Progression-free survival showed high statistical significance, but the overall survival endpoint was not met. The company and analysts say the OS result was affected by frequent crossover of control patients into the tovecimig arm (54%), raising questions about the dataset’s suitability for FDA approval. A pre-BLA meeting in mid‑2026 is expected as the next key milestone, and investors anticipate continued volatility. » Más en de.investing.com
Compass Therapeutics: Tovecimig plus Paclitaxel meets secondary PFS endpoint in cholangiocarcinoma
Compass Therapeutics reports that the combination of Tovecimig and Paclitaxel in the COMPANION-002 study met the secondary endpoint of progression-free survival (median PFS 4.7 vs. 2.6 months) with a hazard ratio of 0.44. The primary endpoint ORR was previously significant at 17.1% vs. 5.3%; overall survival did not reach significance, influenced by a 54% crossover in the control arm. Common adverse events included hypertension, fatigue and neutropenia; Compass plans a meeting with the FDA before a planned regulatory submission and will present the full data at a conference. » Más en de.investing.com
Compass Therapeutics rises after Craig‑Hallum buy recommendation
Compass Therapeutics shares rose 3.1% after Craig‑Hallum initiated coverage with a buy rating and a $15.00 price target. The research firm praised the company’s BsAb approach and highlighted Tovecimig (PD‑1xVEGF‑A) as a potential second‑line agent for cholangiocarcinoma. Craig‑Hallum also pointed to promising early‑phase candidates such as CTX‑8371 and CTX‑10726 and sees further upside over the next 12–18 months as the company transitions to the commercial phase. » Más en de.investing.com
Compass Therapeutics reaches 52-week high at $5.86
Shares of Compass Therapeutics climbed to a new 52-week high of $5.86 and are currently trading at $5.78. Over the past year the stock rose 249.4%, and year-to-date by about 300%, lifting the market capitalization to roughly $1.03 billion. The biotech is not yet profitable but shows strong liquidity with a current ratio of 17.82; analyst price targets range from $8 to $30, while the RSI points to a possible overbought condition. Compass plans to present preclinical data on its bispecific antibody candidate CTX-10726 at the annual meeting of the Society for Immunotherapy of Cancer, which is seen as a significant development step. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | 0 | - |
| Beneficio neto | -23,99 M | 97,42 % |
| EBITDA | -23,65 M | 99,80 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 126,77 M € |
Número de acciones | 180,09 M |
Máximo/mínimo de 52 semanas | 6,26 € - 0,61 € |
| Dividendos | No |
Beta | 0,91 |
Ratio P/E | -1,66 |
Ratio PEG | 68,63 |
Ratio P/B | 1,01 |
Ratio P/S | 0,00 |
Perfil de la empresa
Compass Therapeutics, Inc., una empresa biofarmacéutica en fase clínica centrada en oncología, se dedica al desarrollo de terapias basadas en anticuerpos para tratar diversas enfermedades humanas. Los candidatos a producto de la empresa en fase clínica incluyen CTX-009, un anticuerpo biespecífico en investigación que bloquea las vías de señalización del ligando 4 tipo Delta/Notch y del factor A de crecimiento endotelial vascular, fundamentales para la angiogénesis y la vascularización tumoral; y CTX-471, un anticuerpo monoclonal IgG4 que actúa como agonista de CD137. Sus candidatos a producto también comprenden CTX-8371, un inhibidor biespecífico que se dirige a PD-1 y PD-L1. La empresa fue fundada en 2014 y tiene su sede en Boston, Massachusetts.
| Nombre | COMPASS THERAP. DL-,0001 Aktie |
| CEO | Thomas J. Schuetz |
| Sede | Boston,
ma Estados Unidos |
| Sitio web | |
| Industria | Productos alimenticios |
| Salida a bolsa | 05/04/2021 |
| Empleados | 39 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | CMPX |